European Medicines Agency access to documents practices not in line with good administration, says European Ombudsman

The European Ombudsman has criticised two practices that the European Medicines Agency (EMA) applies when handling access to documents requests.

The first concerns EMA’s handling of certain requests for public access to documents by placing them in a chronological queue. In the Ombudsman’s view, this practice does not meet the requirement in the EU transparency regulation that the EU administration handle access requests promptly.

The second practice concerns EMA restricting individuals to a maximum of five requests in the chronological queue at a given time and limiting each of these requests to no more than two documents. This ‘5-2 rule’ is arbitrary and does not take account of the length, complexity, or total number of documents falling within the scope of individual requests. As a result, the Ombudsman found it to constitute maladministration.

The Ombudsman noted that EMA is already taking steps to phase out the chronological queue and asked the agency to report to her on its progress by 30 March 2024.

The Ombudsman’s findings emerged as part of an inquiry into public access to documents concerning a vaccine for infectious bovine rhinotracheitis. (source: ombudsman.europa.eu/photo: europa.eu)

Read more here

Comments

Popular posts from this blog

Lawyer barred from the ECHR for two years for using inaccurate and non-existent case law via AI

Ombudsman inquiry on Commission President’s text messages is a wake-up call for EU

Questioning Suspects Without a Lawyer: Hungary and Czech Republic Infringed EU Law (CJEU)

Legal Professional Privilege in the Digital Age: Recent case law of the ECtHR and the core principles that should govern searches

Obligation for lawyers to appear in person before disciplinary bodies : Advisory Opinion by ECtHR

International Criminal Court removes Prosecutor Karim Khan over serious misconduct

Early repayment of the loan: Borrower's right to reduction in the total cost of the credit and bank's compensation right